Hybridoma cell strain secreting toxoflavin monoclonal antibody and application of hybridoma cell strain

By optimizing the immunization protocol and magnetic bead sorting technology, a hybridoma cell line GSJTXF-4H3 that secretes toxin-flavin monoclonal antibodies was prepared, solving the problems of long preparation cycle and low efficiency of toxin-flavin monoclonal antibodies, and realizing rapid and accurate detection of toxin-flavin.

CN122038308APending Publication Date: 2026-05-15GUANGZHOU INST FOR FOOD INSPECTION(GUANGZHOU INSPECTION CENT FOR WINE & SPIRITS)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610387399.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-27
Publication Date
2026-05-15

AI Technical Summary

Technical Problem

Existing technologies for preparing monoclonal antibodies specific to flavin have long preparation cycles, low efficiency, high costs, and poor antibody performance, making it difficult to achieve rapid and accurate detection.

Method used

By optimizing the immunization protocol, combining magnetic bead sorting technology to enrich antigen-specific B cells, and using semi-solid culture medium for clonal screening, a hybridoma cell line GSJTXF-4H3 secreting toxin-flavin monoclonal antibody was prepared, simplifying the cumbersome steps of the traditional dilution method and improving the preparation efficiency.

Benefits of technology

The time to obtain stable hybridoma cell lines has been significantly shortened from the traditional 35 days or more to 10-14 days, improving preparation efficiency and yielding monoclonal antibodies with good sensitivity and specificity to toxoflavones, enabling rapid and accurate detection of toxoflavones.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention provides a hybridoma cell strain secreting a toxoflavin monoclonal antibody. The hybridoma cell strain is obtained by immunogen immune animals prepared by coupling toxoflavin hapten and carrier protein. Wherein the carrier protein for preparing the immunogen comprises keyhole limpet hemocyanin KLH. The hybridoma cell strain is preserved in the Guangdong Microbial Culture Collection Center on March 10, 2026, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) No.67912. The invention also provides an application of the hybridoma cell strain, specifically, the toxoflavin monoclonal antibody secreted by the hybridoma cell strain is applied to toxoflavin detection. The kit further comprises a coating antigen, the coating antigen is prepared by coupling the toxoflavin hapten and carrier protein, and the carrier protein for preparing the coating antigen comprises bovine serum albumin (BSA). The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to toxoflavin, and can be accurately and reliably used for quantitative detection of toxoflavin in an actual sample.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of biotechnology and immunoassay, specifically to a hybridoma cell line that secretes a monoclonal antibody against toxoflavin (TF) and its application in the rapid detection of toxoflavin in food. Background Technology

[0002] Toxoflavone (TF) is a bacterial toxin primarily produced by *Burkholderia* species and widely found in grains such as wheat, barley, corn, oats, soybeans, and rice. It often co-occurs with bongkrekic acid (BA), a deadly toxin produced by *Burkholderia gladioli pathovar cocovenenans* (BGC), in contaminated food substrates (such as wet rice noodles, wood ear mushrooms, silver ear mushrooms, and fermented cornmeal). This toxin exerts its toxic effects by interfering with cellular energy metabolism and inducing oxidative damage. Although its lethal risk is far lower than that of bongkrekic acid, as one of the toxins produced by BGC, it remains a significant component of food poisoning risk and poses a serious threat to human health.

[0003] Currently, the detection of toxins mainly relies on instrumental analytical methods, such as high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS / MS), which have the advantages of high accuracy and sensitivity. However, they also have limitations such as expensive equipment, complex operation, cumbersome pretreatment, long detection cycle, and unsuitability for rapid on-site screening and large-scale sample testing. Immunoassays, such as those based on enzyme-linked immunosorbent assay (ELISA), colloidal gold immunochromatography, immunofluorescence quantification, and biosensors, have the advantages of being rapid, simple, low-cost, suitable for on-site and high-throughput screening, and are widely used in the rapid detection of small molecule biotoxins, which is of great significance for ensuring food safety. The prerequisite for using immunoassay technology is to obtain monoclonal antibodies with high affinity and high specificity. In the process of monoclonal antibody preparation, there are prominent problems such as the extremely low proportion of specific B cells in spleen cells, difficulty in screening positive clones after cell fusion, and the cumbersome and long cycle (usually more than 35 days) of the traditional limiting dilution subcloning step, which is easily affected by non-specific clones, resulting in low screening efficiency and high cost. Therefore, it is crucial to develop a monoclonal antibody that can accurately detect toxins by improving and optimizing existing preparation methods, which is of great significance for promoting the development of toxin immunoassay technology. Summary of the Invention

[0004] Therefore, the technical problem to be solved by this invention is to develop a monoclonal antibody capable of accurately detecting toxoflavones, overcoming the problems of long preparation cycles, low efficiency, high costs, and poor antibody performance of existing toxoflavone-specific monoclonal antibodies. To solve the above technical problems, this invention provides a hybridoma cell line that secretes a toxoflavone monoclonal antibody and its application, as detailed below:

[0005] The first objective of this invention is to provide a hybridoma cell line that secretes a monoclonal antibody against flavin, obtained by immunizing animals with an immunogen prepared by conjugating a flavin hapten with a carrier protein, wherein the structural formula of the flavin hapten is shown in Formula I:

[0006] Ⅰ

[0007] Furthermore, the carrier protein used to prepare the immunogen includes keyhole hemocyanin (KLH).

[0008] Furthermore, the hybridoma cell line GSJTXF-4H3 was deposited at the Guangdong Provincial Center for Microbial Culture Collection on March 10, 2026, with accession number GDMCC No. 67912.

[0009] Furthermore, the animal is a BALB / c mouse.

[0010] The second objective of this invention is to provide an application of the hybridoma cell line GSJTXF-4H3 that secretes the toxoflavone monoclonal antibody, specifically, the toxoflavone monoclonal antibody secreted by the hybridoma cell line GSJTXF-4H3 is used to detect toxoflavone.

[0011] Furthermore, the toxoflavone monoclonal antibody is of the IgG1 subtype.

[0012] Furthermore, the toxoflavone monoclonal antibody is used to detect toxoflavones in food.

[0013] Furthermore, it also includes a coating agent, which is prepared by coupling a toxin flavin hapten with a carrier protein.

[0014] Furthermore, the carrier protein used to prepare the coating antigen includes bovine serum albumin (BSA).

[0015] This invention has the following outstanding substantive features and significant progress:

[0016] 1. This invention optimizes the immunization protocol and combines it with magnetic bead sorting technology to enrich antigen-specific B cells, effectively increasing the abundance of specific B cells before fusion. After fusion, semi-solid culture medium is used for clonal screening, which allows for direct selection of single clones and avoids the cumbersome steps of multiple rounds of subcloning in the traditional limiting dilution method. This shortens the time to obtain stable hybridoma cell lines from more than 35 days to 10–14 days, significantly improving the preparation efficiency.

[0017] 2. This invention screened and obtained a hybridoma cell line, GSJTXF-4H3. The monoclonal antibody secreted by the hybridoma cell line GSJTXF-4H3 of this invention has good sensitivity and specificity against toxin. Specifically, the IC50 of toxin is... 50 The value was 10.4 ng / mL, and there was no cross-reactivity with aflatoxin B1, ochratoxin A, zearalenone, fumonisin B1, bongkrekic acid, okata sponge acid, and bryophylloidin A, thus enabling efficient and rapid detection of toxins. Attached Figure Description

[0018] Figure 1 The image shows the ultraviolet scanning identification of the toxoflavone immunogen prepared in Example 1 of this invention. The absorption spectrum curves of keyhole hemocyanin (KLH), toxoflavone, and the prepared toxoflavone immunogen (TF-KLH) are marked in the image. The toxoflavone-KLH marked in the image corresponds to the toxoflavone immunogen (TF-KLH).

[0019] Figure 2 The image shows the ultraviolet scanning identification of the toxin-coated progenitor prepared in Example 1 of this invention. The absorption spectrum curves of bovine serum albumin (BSA), toxin, and the prepared toxin-coated progenitor (TF-BSA) are marked in the image. The toxin-BSA marked in the image corresponds to the toxin-coated progenitor (TF-BSA).

[0020] Figure 3 The inhibition curve of the toxin-containing monoclonal antibody is shown.

[0021] Figure 4 This is the standard curve for toxic flavin. Detailed Implementation

[0022] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, so that those skilled in the art can better understand and implement the present invention. However, the embodiments are not intended to limit the present invention. Unless otherwise specified, the reagents and culture media used in the following embodiments are all commercially available products commonly used in the art.

[0023] The culture media and solutions involved in the following examples:

[0024] Toxoflavone standard, RPMI-1640 basal medium, fetal bovine serum (FBS), HAT supplement, HT supplement, 50% polyethylene glycol (PEG 1500) cell fusion agent, carbonate buffer (CBS, 0.05 M, pH 9.6), phosphate buffer (PBS, 0.01 M, pH 7.4), wash buffer (PBST containing 0.05% Tween-20), blocking buffer (PBST containing 3% BSA or 5% skim milk powder), TMB chromogenic solution, Termination solution, mouse monoclonal antibody subtype identification kit, and BCA concentration assay kit. Their preparation methods can be found in accordance with standard practices in the field or commercial instructions.

[0025] The detection methods involved in the following embodiments Indirect competitive ELISA (ic-ELISA): Used to determine mouse serum titers, screen hybridoma cell supernatants, and identify monoclonal antibody IC50. 50 And cross-reactivity rate. The basic steps are as follows: Coat the ELISA plate with a coating antigen (toxoflavin-BSA), block it, add a series of concentrations of toxoflavin standards (or test samples) and monoclonal antibodies of fixed dilution to the wells, which compete for binding to the antigenic epitopes on the coating antigen. After washing, add enzyme-labeled secondary antibody and substrate for color development, and measure the OD value. Plot the logarithm of the standard concentration on the x-axis, and plot the cross-reactivity rate on the y-axis. Plot a standard curve with % as the ordinate and calculate... Cross-reactivity rate .

[0026] Example 1: Synthesis of Toxoflavone Hapten Derivatives and Artificial Antigens

[0027] A hybridoma cell line secreting a monoclonal antibody against flavin is obtained by immunizing animals with an immunogen prepared by conjugating a flavin hapten with a carrier protein. The carrier protein used to prepare the immunogen includes keyhole hemocyanin (KLH). The animal is a BALB / c mouse.

[0028] Since toxin is a small molecule hapten, it needs to be derivatized and coupled to a carrier protein to acquire immunogenicity. A derivative (with the general structural formula shown in Formula I) with a carboxyl active group introduced into the toxin molecule was designed and synthesized as a hapten (TF-COOH). The specific steps are as follows:

[0029] First, preparation of the immunogen (TF-KLH) and coating antigen (TF-BSA):

[0030] Step 1, Preparation of hapten: Weigh 2.0 mg of toxoflavone and 4.0 mg of carboxymethyl hydroxylamine hemihydrochloride (CMO), dissolve them in 2 mL of pyridine-methanol mixed solution (0.5 mL pyridine + 1.5 mL methanol), and react with shaking at room temperature in the dark for 12 h. After rotary evaporation of the reactants, add 2 mL of double-distilled water, adjust the pH of the aqueous phase to 4.0, extract the toxoflavone oxime with ethyl acetate, and concentrate to obtain the hapten toxoflavone-CMO, with the structural formula shown in Formula I.

[0031]

[0032] Formula I

[0033] Step 2, Conjugation of Toxoflavone Immunogen (TF-KLH): Dissolve 0.5 mg of toxoflavone-CMO in 0.3 mL of DMF-water (6:9 volume ratio), add 1.0 mg of EDC, and react at room temperature in the dark for 4 hours with stirring. Then add another 1.0 mg of EDC. Add a 0.5% keyhole hemocyanin KLH solution prepared with phosphate buffer to the reaction solution and continue the reaction for 24 hours under the same conditions. Centrifuge the reaction product and dialyze it with phosphate buffer for 72 hours, changing the dialysate every 12 hours. Store at 4°C for later use. Remove unreacted small molecules to obtain a relatively pure complete antigen, i.e., immunogen TF-KLH.

[0034] The obtained immunogen TF-KLH was identified by ultraviolet absorption scanning, and the results are shown in the figure. Figure 1 The immunogen TF-KLH was aliquoted and stored at -20°C. The immunogen TF-KLH described in the following examples was prepared using the method described in this step.

[0035] Step 3: Preparation of Toxoflavin-Coated Origin (TF-BSA): 1.0 mg of toxoflavin-CMO, 0.4 mg of N-hydroxysuccinimide, and 0.6 mg of dicyclohexylcarbodiimide were dissolved in anhydrous tetrahydrofuran. The mixture was reacted with shaking at 30°C for 1 h. After centrifugation, the precipitate was washed three times with anhydrous tetrahydrofuran. The supernatant was collected and purged with nitrogen. 0.2 mL of dimethylformamide was added to dissolve the residue. This solution was then added to a 0.5% bovine serum albumin (BSA) solution prepared with phosphate buffer. The reaction was carried out at room temperature in the dark for 24 h. After centrifugation, the reaction product was dialyzed against phosphate buffer for 72 h, with the dialysate changed every 12 h. The solution was stored at 4°C for later use. Unreacted small molecules were removed to obtain the coated origin TF-BSA.

[0036] The coated original TF-BSA was identified by ultraviolet absorption scanning, and the results are shown in the figure. Figure 2 The coated TF-BSA was then aliquoted and stored at -20°C. The coated TF-BSA in all the following embodiments was prepared using the method described in this step.

[0037] Example 2: Animal Immunization

[0038] Animals were immunized using the immunogen TF-KLH prepared in Example 1, and the specific steps are as follows:

[0039] Healthy female BALB / c mice aged 6-8 weeks were selected and immunized via subcutaneous multi-site injection. First immunization: Immunogen TF-KLH was thoroughly emulsified with an equal volume of Freund's complete adjuvant, and 100 μg (based on protein) was injected into each mouse. Booster immunization: 21 days apart, the antigen was emulsified using Freund's incomplete adjuvant at half the dose (50 μg / mouse), for a total of 3 booster immunizations. Seven days after the last immunization, blood was collected from the tail vein, serum was separated, and serum titer and inhibition rate against toxicoflavones were determined using ic-ELISA. Mice with high titers (>1:64000) and good inhibition (>70%) were selected for cell fusion (as shown in Table 1).

[0040] Shock immunization: Selected immunized mice were intraperitoneally injected with adjuvant-free immunogen TF-KLH solution (50 μg / mouse) 3 days before fusion.

[0041] Table 1. Determination of antibody titers in serum of immunized mice by indirect ELLSA method

[0042]

[0043] Example 3: Spleen cell preparation and antigen-specific B cell enrichment Three days after the initial immunization, spleens were aseptically harvested and single-cell suspensions were prepared. Using a commercially available mouse B-cell positive screening kit and magnetic bead sorting technology, non-B cells such as T cells and macrophages were removed from the spleen cell suspension to obtain a relatively enriched B-cell population for subsequent fusion, thereby improving the positive rate of specific hybridomas.

[0044] Example 4: Cell fusion and semi-solid culture medium screening Enriched spleen cells from immunized mice were mixed with SP2 / 0 mouse myeloma cells in logarithmic growth phase at a ratio of 5:1 to 10:1. Cell fusion was performed using 50% PEG 1500 as a fusion agent, following standard procedures. After fusion, the cells were resuspended in RPMI-1640 selection medium containing 20% ​​FBS and 1×HAT. The fused cell suspension was then mixed with pre-warmed semi-solid cloning medium (ClonaCell™-HY) according to the manufacturer's instructions, gently mixed, and evenly spread in sterile culture dishes. The mixture was incubated at 37°C. Incubate in a saturated humidity incubator for 10-14 days. In a semi-solid culture medium, individual surviving hybridoma cells can proliferate to form independent, visible cell clonal colonies.

[0045] After 10 days of culture, under a microscope, well-dispersed and vigorously growing single clonal colonies were carefully picked up using sterile pipette tips or cloning loops and transferred to 96-well plates. Each well was then filled with RPMI-1640 medium containing 20% ​​FBS and 1×HT for amplification. The cell supernatant was analyzed using ELISA until all wells containing cell clusters were positive, yielding a hybridoma cell line secreting toxin-flavin monoclonal antibodies.

[0046] Example 5: Screening and subcloning of hybridoma cells

[0047] When the clones in the 96-well plate had grown to cover approximately one-third of the bottom area of ​​each well, the cell supernatant was aspirated, and initial screening was performed using ic-ELISA: using TF-BSA as the coating antigen and toxoflavone standard as a competitor, positive wells were selected to secrete antibodies that specifically bind to toxoflavone and can be competitively inhibited by free toxoflavone. For the initially screened positive wells, subcloning was immediately performed using the limiting dilution method to ensure monoclonal integrity.

[0048] Cells from positive wells were serially diluted and seeded into 96-well plates, with a theoretical cell count of approximately one per well. After culturing for 7-10 days, the supernatant was analyzed again using ic-ELISA. Wells with 100% positive rates were selected, and subcloning was repeated 2-3 times until a hybridoma cell line stably secreting toxin-flavin monoclonal antibody was obtained, named GSJTXF-4H3. This hybridoma cell line was expanded and cryopreserved, and then submitted to the Guangdong Provincial Microbial Culture Collection Center for preservation.

[0049] Biological Preservation Instructions:

[0050] The hybridoma cell line GSJTXF-4H3, classified as: hybridoma cell line of toxoflavone monoclonal antibody GSJTXF-4H3, is deposited at Guangdong Provincial Microbial Culture Collection Center, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Guangdong Province, on March 10, 2026. The depositary code is GDMCC-Guangdong Provincial Microbial Culture Collection Center, and the accession number is GDMCC No. 67912.

[0051] Example 6: Preparation and purification of monoclonal antibodies

[0052] 8-10 week old BALB / c mice were pretreated by intraperitoneal injection of 0.5 mL of sterile paraffin oil. Seven days later, each mouse was injected intraperitoneally with 5 × 10⁻⁶ g of paraffin oil. 5 Up to 1×10 6TF-4H3 hybridoma cells were collected. Approximately 10-14 days later, the mice's abdomens became distended, and ascites fluid was collected. The ascites fluid was centrifuged at 3000 rpm for 10 minutes to remove cell debris. The supernatant was used to purify monoclonal antibodies using the Protein G method, following the specific steps outlined in the Molecular Cloning Laboratory Manual. The purified monoclonal antibodies were dialyzed against PBS to determine protein concentration, aliquoted, and stored at -80°C or -20°C.

[0053] Example 7: Identification of Monoclonal Antibodies

[0054] 1. Titer Assay: The titer of the purified monoclonal antibody was determined using an indirect ELISA. The original TF-BSA-coated ELISA plate was coated, and the antibody was serially diluted from 1:2000 and added to the wells for reaction. The results (as shown in Tables 2 and 3) indicate that the titer of this monoclonal antibody is greater than 1:64 × 10⁻⁶. 3 .

[0055] Table 2. Checkerboard titration results for optimal antibody coating concentration and antibody dilution factor.

[0056]

[0057] Table 3 Monoclonal antibody titer results

[0058]

[0059] 2. Subtype identification: The mouse monoclonal antibody subtype identification kit was used to determine that the antibody was IgG1.

[0060] κ light chain type (as shown in Table 4).

[0061] Table 4. Monoclonal antibody subtype identification OD 450 value

[0062]

[0063] 3. Determination: The optimal concentrations of antibody and coating antigen were determined using the checkerboard method (as shown in Table 2). The ic-ELISA method was employed. Toxoflavone standards were diluted with PBS to prepare concentration gradients of 0 ng / mL, 0.00305 ng / mL, 0.00610 ng / mL, 0.01220 ng / mL, 0.02441 ng / mL, 0.04882 ng / mL, 0.09765 ng / mL, and 0.19531 ng / mL. The logarithm of toxoflavone concentration was plotted on the x-axis. % represents the vertical axis (B is the OD value of the sample with holes added). To obtain the OD values ​​of the control wells without adding the analyte, a standard inhibition curve (e.g.) is plotted. Figure 3 (As shown). Calculations show that this monoclonal antibody is effective against toxin-containing compounds. It was 10.4 ng / mL.

[0064] 4. Antibody protein concentration determination: The protein concentration of the purified antibody was determined using a BCA concentration assay kit. The concentration was calculated based on the BCA standard curve equation: Y = 0.0453X + 0.0341(R²). 2 =0.9993), which yielded a purified antibody protein concentration of 4.52 mg / mL.

[0065] 5. Specificity (Cross-reactivity) determination: Using the same ic-ELISA method, the specificity of this monoclonal antibody against common fungal toxins such as aflatoxin B1, ochratoxin A, zearalenone, fumonisin B1, bongkrekic acid, okata spore acid, and bryophylloidin A, as well as bongkrekic acid, was determined. The cross-reactivity rate (CR%) was calculated, and the results are shown in Table 1, where ND indicates that the target substance was not detected in the detection (as shown in Table 5).

[0066] Table 5. Specificity analysis of monoclonal antibodies

[0067]

[0068] Example 8: Application of Toxoflavone Monoclonal Antibody

[0069] A monoclonal antibody against toxin, prepared from hybridoma cell lines via in vivo ascites fluid, was used in a product for detecting toxin. This product, in addition to the aforementioned monoclonal antibody, also included a coating antigen, which was prepared by conjugating a toxin hapten to a carrier protein. The carrier protein used to prepare the coating antigen was bovine serum albumin (BSA). The product was then applied to a toxin-detecting ELISA assay for toxic flavin, with the following specific steps:

[0070] 1. Coat a 96-well microplate with 0.625 μg / mL of original TF-BSA diluted with carbonate buffer (CBS), 100 μL per well. Incubate at 37°C for 2 h. Wash the plate three times with PBST wash buffer, 200 μL per well each time, for 3 min each time. Pat dry.

[0071] 2. Block with CBS containing 0.2% gelatin, 200 μL per well, dry at 37°C for 2 h, wash the plate three times with PBST washing solution, 200 μL per well each time, 3 min each time, and pat dry.

[0072] 3. Prepare 0 ng / mL, 0.00305 ng / mL, 0.00610 ng / mL, 0.01220 ng / mL, 0.02441 ng / mL, 0.04882 ng / mL, 0.09765 ng / mL and 0.19531 ng / mL toxoflavone standard solutions using phosphate-buffered saline (PBS). Add the standard solutions and the extracts of the samples to be tested to the pre-blocked ELISA plates, 50 μL per well, with each sample repeated in 3 wells. Add 50 μL of toxoflavone monoclonal antibody to each well. Incubate at 37°C for 30 min, then wash and blot dry.

[0073] 4. Add 100 μL of HRP-labeled goat anti-mouse IgG secondary antibody diluted 1:10000 with PBS containing 0.1% gelatin to each well, react at 37°C for 30 min, then wash the plate and pat dry.

[0074] 5. Add 100 μL of TMB colorimetric solution to each well, develop the color at 37℃ for 10 min, then add 50 μL of 2 mol / L H2SO4 stop solution to each well, and measure the absorbance at 450 nm.

[0075] Spiked Recovery: Rice noodles and white fungus were selected as test samples. Toxicoflavin standards were added to a final concentration of 1 mg / kg, and the ic-ELISA method was used for testing. A standard curve was plotted with the absorbance of the standards on the ordinate and the logarithm of the standard concentration (ng / mL) on the abscissa (see [link to standard curve]). Figure 4 The standard curve equation for toxoflavone was obtained as Y = -1.9771X + 4.4365 (R² = 0.9959). The absorbance readings of the samples were substituted into the curve, and the result was multiplied by the dilution factor to obtain the actual concentration of toxoflavone in the samples. The calculated recoveries were 109% (rice noodles) and 94% (white fungus), with a relative standard deviation (RSD) of less than 10%. This indicates that the monoclonal antibody provided by this invention and the ELISA method established based on it can be accurately and reliably used for the quantitative detection of toxoflavone in actual samples.

[0076] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.

Claims

1. A hybridoma cell line that secretes a monoclonal antibody against toxin flavin, characterized in that, The immunogen, prepared by conjugating a toxin flavin hapten with a carrier protein, is used to immunize animals. The structural formula of the toxin flavin hapten is shown in Formula I.

2. The hybridoma cell line secreting toxin-flavin monoclonal antibody according to claim 1, characterized in that, The carrier protein used to prepare the immunogen includes keyhole hemocyanin (KLH).

3. The hybridoma cell line secreting toxin-flavin monoclonal antibody according to claim 1, characterized in that, The hybridoma cell line GSJTXF-4H3 was deposited at the Guangdong Provincial Center for Microbial Culture Collection on March 10, 2026, with accession number GDMCC No. 67912.

4. The hybridoma cell line secreting toxin-flavin monoclonal antibody according to claim 1, characterized in that, The animal in question was a BALB / c mouse.

5. The application of the hybridoma cell line secreting toxin-flavin monoclonal antibody according to any one of claims 1 to 4, characterized in that, The monoclonal antibody against toxin secreted by the hybridoma cell line is used to detect toxin.

6. The application of the hybridoma cell line according to claim 5, characterized in that: The toxin-flavin monoclonal antibody is of the IgG1 subtype.

7. The application of the hybridoma cell line according to claim 6, characterized in that: The toxin monoclonal antibody is used to detect toxins in food.

8. The application of the hybridoma cell line according to claim 7, characterized in that, It also includes coating antigens, which are prepared by coupling toxin flavin hapten with a carrier protein.

9. The application of the hybridoma cell line according to claim 8, characterized in that, The carrier protein used to prepare the coating antigen includes bovine serum albumin (BSA).